{"d":{"__metadata":{"id":"https://ws.parlament.ch/OData.svc/Business(ID=20165549,Language='DE')","uri":"https://ws.parlament.ch/OData.svc/Business(ID=20165549,Language='DE')","type":"itsystems.Pd.DataServices.DataModel.Business"},"BusinessResponsibilities":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20165549,Language='DE')/BusinessResponsibilities"}},"RelatedBusinesses":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20165549,Language='DE')/RelatedBusinesses"}},"BusinessRoles":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20165549,Language='DE')/BusinessRoles"}},"Publications":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20165549,Language='DE')/Publications"}},"LegislativePeriods":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20165549,Language='DE')/LegislativePeriods"}},"Sessions":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20165549,Language='DE')/Sessions"}},"Preconsultations":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20165549,Language='DE')/Preconsultations"}},"Bills":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20165549,Language='DE')/Bills"}},"Councils":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20165549,Language='DE')/Councils"}},"BusinessTypes":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20165549,Language='DE')/BusinessTypes"}},"Votes":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20165549,Language='DE')/Votes"}},"SubjectsBusiness":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20165549,Language='DE')/SubjectsBusiness"}},"BusinessStates":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20165549,Language='DE')/BusinessStates"}},"Council":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20165549,Language='DE')/Council"}},"Transcripts":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20165549,Language='DE')/Transcripts"}},"ID":20165549,"Language":"DE","BusinessShortNumber":"16.5549","BusinessType":14,"BusinessTypeName":"Fragestunde. Frage","BusinessTypeAbbreviation":"Fra.","Title":"Avastin. Warum wird das effiziente und preiswerte Medikament nicht zugelassen?","Description":null,"InitialSituation":null,"Proceedings":null,"DraftText":null,"SubmittedText":"<p>F\u00fcr die Behandlung von Altersblindheit gibt es ein Medikament, Avastin. Dieses ist f\u00fcr diese Indikation jedoch nicht zugelassen, und die \u00c4rzte m\u00fcssen das 40-mal teurere Lucentis verschreiben!</p><p>- Warum verlangen die Beh\u00f6rden keine klinischen Vergleichsstudien im Hinblick darauf, den Einsatz von Avastin wieder zuzulassen, wie es in den USA der Fall war?</p><p>- In Frankreich, Italien und den USA ist die R\u00fcckerstattung der Kosten von Avastin f\u00fcr die Behandlung von altersbedingter Makuladegeneration erlaubt. Warum nicht in der Schweiz?</p>","ReasonText":null,"DocumentationText":null,"MotionText":null,"FederalCouncilResponseText":null,"FederalCouncilProposal":null,"FederalCouncilProposalText":null,"FederalCouncilProposalDate":null,"SubmittedBy":"Fehlmann Rielle Laurence","BusinessStatus":229,"BusinessStatusText":"Erledigt","BusinessStatusDate":"\/Date(1481500800000)\/","ResponsibleDepartment":4,"ResponsibleDepartmentName":"Departement des Innern","ResponsibleDepartmentAbbreviation":"EDI","IsLeadingDepartment":true,"Tags":"2841","Category":null,"Modified":"\/Date(1690520347913)\/","SubmissionDate":"\/Date(1480982400000)\/","SubmissionCouncil":1,"SubmissionCouncilName":"Nationalrat","SubmissionCouncilAbbreviation":"NR","SubmissionSession":5006,"SubmissionLegislativePeriod":50,"FirstCouncil1":null,"FirstCouncil1Name":null,"FirstCouncil1Abbreviation":null,"FirstCouncil2":null,"FirstCouncil2Name":null,"FirstCouncil2Abbreviation":null,"TagNames":"Gesundheit"}}